Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
A Randomized, Double-Blind Placebo-Controlled Phase 2 Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Typ studie
Typ studie
Zápis (Aktuální)
Zápis
Fáze
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
-
Saint Grégoire, Francie, 35768
- Centre Hospitalier Privé Saint Grégoire
-
-
Cedex
-
Colmar, Cedex, Francie, 68024
- Hôpitaux civils de Colmar
-
Lyon, Cedex, Francie, 69437
- Hôpital Edouard Herriot
-
Rennes, Cedex, Francie, 35042
- Service d'Oncologie Médicale
-
-
-
-
-
Genova, Itálie
- Ospedale San Martino
-
Lecce, Itálie
- Unita Operativa di Oncologia Medica
-
Siena, Itálie, 53100
- Policlinico Santa Maria alle Scotte
-
Udine, Itálie, 33100
- Azienda Ospedaliero Universitaria Santa Maria della Misericordia
-
-
Torino
-
Candiolo, Torino, Itálie, 10060
- Institute for Cancer Research and Treatment - IRCC
-
-
-
-
-
Donauwörth, Německo, 86609
- Onkologische Praxis Donauwörth
-
Halle, Německo, 06120
- Universitätsklinikum Halle Klinik und Poliklinik für Innere Medizin
-
München, Německo, 81675
- Klinikum rechts der Isar
-
-
-
-
-
Bialystok, Polsko, 15-027
- Bialostockie Centrum Onkologii im. Marii Sklodowskiej-Curie w Bialymstoku
-
Bytom, Polsko, 41-902
- Wojewodzki Szpital Specjalistyczny
-
Gliwice, Polsko, 44-101
- Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie
-
Krakow, Polsko, 31-108
- VESALIUS Sp. z o.o.
-
Warszawa, Polsko, 01-002
- NZOZ ONKOLOG s.c.
-
-
-
-
-
Moscow, Ruská Federace, 125367
- Central Clinical Hospital #1
-
Moscow, Ruská Federace, 115478
- Russian Oncology Research Centre n.a. Blokhin, RAMS
-
Moscow, Ruská Federace, 129128
- NUZ Semashko Central Clinical Hospital
-
St Petersburg, Ruská Federace, 198255
- St-Petersburg State Institution of Public Health
-
St-Petersburg, Ruská Federace, 194291
- Federal State Institution of Healthcare Clinical Hospital # 122 n.a.L.G Sokolov
-
Tula, Ruská Federace, 300053
- Tula Regional Oncology Dispensary
-
-
Kaluga
-
Obninsk, Kaluga, Ruská Federace, 249030
- Medical Radiological Research Centre
-
-
Tatarstan
-
Kazan, Tatarstan, Ruská Federace, 4200111
- Kazan State Medical University
-
-
-
-
-
Aberdeen, Spojené království, AB25 2ZN
- Aberdeen Royal Infirmary
-
London, Spojené království, EC1A 7BE
- St.Bartholomew's Hospital
-
London, Spojené království, NW1 2PQ
- UCLH Cancer Clinical Trials Unit
-
Manchester, Spojené království, M20 4BX
- Christie Hospital
-
-
Middlesex
-
Northwood, Middlesex, Spojené království, HA6 2RN
- Mount Vernon Cancer Centre
-
-
-
-
-
Kiev, Ukrajina, 03115
- Kyiv City Oncology Hospital
-
Sumy, Ukrajina, 40005
- Sumy Regional Oncology Center
-
-
Volyn
-
Lutsk, Volyn, Ukrajina
- Volyn Regional Oncology Dispensary
-
-
-
-
-
Brno, Česko, 62500
- Fakulti nemocnice Brno
-
Olomouc, Česko, 77520
- Fakultni Nemocnice Olomouc
-
Znojmo, Česko, 66902
- Nemocnice Znojmo, p.o., Oddeleni radiacni a klinicke onkologie
-
-
-
-
-
Pamplona, Španělsko, 31008
- Clinica Universitaria de Navarra
-
Terrassa (Barcelona), Španělsko, 08221
- Hospital Mútua de Terrassa
-
-
Villaroel
-
Barcelona, Villaroel, Španělsko, 170
- H.Clinic I Provincial de Barcelona
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Patients with histologically confirmed, metastatic CRC that have achieved confirmed maximal benefit of DC following treatment with standard first line chemotherapy of a 5-fluoropyrimidine plus either oxaliplatin or irinotecan. Patients should be entered onto this trial within 8 weeks of completing first line therapy;
- If CR was not achieved: measurable disease, i.e. at minimum one unidimensionally-measurable target lesion according to RECIST (Response Evaluation Criteria in Solid Tumors);
- Age >= 18 years and Eastern Cooperative Oncology Group (ECOG) performance status (PS) =< 2 at study entry;
- Resolution of any toxic effects of prior therapy (except alopecia) to NCI CTCAE, Version 3.0, grade =< 1;
Adequate organ and bone marrow function as evidenced by:
- Haemoglobin >= 10 g/dL (transfusion and/or growth factor support allowed);
- Absolute neutrophil count (ANC) >= 1.5 x 109/L;
- Platelet count >= 100 x 109/L;
- Serum creatinine =< 1.5 x ULN or creatinine clearance >60 mL/min;
- AST and alkaline phosphatase <2.5 x ULN if without liver metastasis and =< 5.0 x ULN if liver metastasis;
- Total bilirubin =< 2.0 x ULN;
- Prothrombin time (PT)/International Normalised Ratio (INR) within normal limits (WNL) unless therapeutically anticoagulated;
- Women of childbearing potential and men must be willing to consent to using highly effective methods of contraception (eg, hormonal contraceptives, bilateral tubal ligation, barrier with spermicide, intrauterine device) while on treatment and for at least 3 months thereafter;
- Males with the potential to father children must use two of the following methods of contraception acceptable for the study (e.g. hormonal contraceptives, bilateral tubal ligation, barrier with spermicide, intrauterine device) while on trial treatment and for at least 3 months thereafter.
- All female subjects of childbearing potential must have a negative pregnancy test (plasma or urine) result within 7 days before initiating study treatment;
- Baseline laboratory tests and tumor assessments must have been performed within 2 weeks before initiating study treatment;
- Subjects must be fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects) and must sign and date an IEC-approved ICF before performance of any study specific procedures or tests.
Exclusion Criteria:
- Anticipation of need for a major surgical procedure or RT during the study;
- Treatment with chemotherapy, hormonal therapy, minor surgery, or any investigational agent within 4 weeks before study enrolment. Treatment with immunotherapy, biological therapy, or major surgery within 6 weeks before study enrolment. Treatment with RT within 1 week before study enrolment.
- History of any of the following conditions: diabetes mellitus requiring treatment with insulin or oral agents;
- Concomitant use of other TZDs;
- Myocardial infarction with significant impairment of cardiac function (e.g., ejection fraction =< 50%); severe/unstable angina pectoris; coronary/peripheral artery bypass graft; congestive heart failure; cerebrovascular accident (CVA) or transient ischemic attack (TIA), pulmonary embolism, or other clinically significant thromboembolic event; clinically significant pulmonary disease (e.g., severe chronic obstructive pulmonary disease [COPD] or asthma);
- Brain metastasis; an uncontrolled seizure disorder; spinal cord compression; or carcinomatous meningitis;
- Pleural or pericardial effusion. Subjects with minimal pleural effusion may be eligible upon request by Investigator and approval by Sponsor;
- Clinically significant active infection that requires antibiotic therapy or Human Immunodeficiency Virus (HIV) positive subjects receiving antiretroviral therapy;
- Pregnant or breast feeding;
- Known history of severe hypersensitivity reactions to any of the components of CS 7017 formulations;
- Serious intercurrent medical or psychiatric illnesses or any other conditions that in the opinion of the Investigator would impair the ability to give informed consent or unacceptably reduce protocol compliance or safety of the study treatment;
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Trojnásobný
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: CS-7017
|
CS-7017
|
|
Komparátor placeba: Placebo
Placebo matching CS-7017
|
Placebo
|
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Percentage Rate of Progression-free Survival at 18 Weeks Following Use of CS-7017 in Colorectal Cancer Participants Who Have Achieved Disease Control Following First-Line Chemotherapy
Časové okno: 18 weeks postdose
|
Progression-free survival (PFS) was defined as the time from enrollment to the date of the first objective documentation of disease progression or death resulting from any cause, whichever comes first.
Progression was defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) as at least a 20% increase in the sum of diameters of target lesions.
|
18 weeks postdose
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Percentage Rate of Progression-free Survival Following Use of CS-7017 in Colorectal Cancer Participants Who Have Achieved Disease Control Following First-Line Chemotherapy
Časové okno: At 12, 24, and 30 weeks postdose
|
Progression-free survival (PFS) was defined as the time from enrollment to the date of the first objective documentation of disease progression or death resulting from any cause, whichever comes first.
Progression was defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) as at least a 20% increase in the sum of diameters of target lesions.
|
At 12, 24, and 30 weeks postdose
|
|
Percentage Rate of Overall Survival Following Use of CS-7017 in Colorectal Cancer Participants Who Have Achieved Disease Control Following First-Line Chemotherapy
Časové okno: At 3, 6, 9, and 12 months postdose
|
Overall survival (OS) was defined as the time from the date of enrollment to the date of death and assessed by Kaplan Meier analysis.
|
At 3, 6, 9, and 12 months postdose
|
|
Best Overall Response and Objective Response Rate Following Use of CS-7017 in Colorectal Cancer Participants Who Have Achieved Disease Control Following First-Line Chemotherapy
Časové okno: From baseline up to disease progression or the development of unacceptable toxicity (whichever occurs first), up to approximately 3 years 3 months
|
The best overall response was defined as the best response (in the order of confirmed complete response [CR], confirmed partial response [PR], unconfirmed CR, unconfirmed PR, stable disease [SD], and progressive disease [PD]) among all overall responses recorded from the start of treatment until the participant withdrew from the study.
If there was no tumor assessment after the first dose of study drug, the best overall response was classified as Inevaluable.
Based on RECIST v1.0, CR was defined as a disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, and SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions.
|
From baseline up to disease progression or the development of unacceptable toxicity (whichever occurs first), up to approximately 3 years 3 months
|
|
Duration of Response for Responding Participants Following Use of CS-7017 in Colorectal Cancer Participants Who Have Achieved Disease Control Following First-Line Chemotherapy
Časové okno: From the date of first objective response (confirmed and unconfirmed CR or PR) to date of progressive disease, up to 3 years 3 months
|
Duration of response was defined for participants with confirmed CR or PR and confirmed and unconfirmed CR or PR as the time from the date of the first documentation of objective response (CR or PR) to the date of the first documentation of progressive disease.
Duration of SD was defined for participants whose best response was SD as the time from the randomization date to the date of the first documentation of progressive disease.
Duration of response was estimated using Kaplan Meier methods.
|
From the date of first objective response (confirmed and unconfirmed CR or PR) to date of progressive disease, up to 3 years 3 months
|
|
Number of Participants With Treatment-Emergent Adverse Events Related to Study Drug With an Incidence of ≥5% Following Use of CS-7017 Or Placebo in Colorectal Cancer Participants Who Have Achieved Disease Control Following First-Line Chemotherapy
Časové okno: Baseline up to 30 days after last study dose, up to 3 years 3 months
|
A treatment-emergent adverse event (TEAE) was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment.
If relationship is missing, the AE is also considered to be related to the drug.
|
Baseline up to 30 days after last study dose, up to 3 years 3 months
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Aktuální)
Primární dokončení
Dokončení studie (Aktuální)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- CS7017-A-E201
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Časový rámec sdílení IPD
Kritéria přístupu pro sdílení IPD
Typ podpůrných informací pro sdílení IPD
- PROTOKOL STUDY
- MÍZA
- CSR
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .